Xenetic Biosciences Announces Opening of Corporate Headquarters and R&D Facility in Lexington, MA

March 4, 2014

For Immediate Release:

LEXINGTON, Mass., March 4, 2014 – Xenetic Biosciences, Inc. (OTCBB: XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced the opening of its new corporate headquarters and research and development facility in Lexington, MA. Xenetic, in collaboration with the Massachusetts Life Sciences Center (MLSC) and the Massachusetts Biotechnology Council (MassBio), will host a grand opening and ribbon cutting ceremony today to celebrate the completion of the Company’s relocation of its global headquarters to Lexington from London, UK.

The relocation decision follows the March 2011 visit to the UK by Governor Deval Patrick and a delegation of state leaders from industry, academia and government to promote mutually beneficial collaborations. The first discussion with Xenetic took place during that trade mission. The company currently has 7 employees in Lexington with plans to grow to 14 by the end of 2014.

Scott Maguire, CEO of Xenetic said, “The opening of Xenetic’s new corporate headquarters in Lexington marks an important new phase in the Company’s 17 year history. Moving our development operations to the Massachusetts biotech corridor is an important step in our transition to becoming an innovative biopharmaceutical company based and publicly listed in the U.S. We believe that we are much more strongly positioned to execute on our mission to develop and commercialize leading next-generation biologic drugs and novel oncology therapeutics.”

Ceremony attendees included local officials and legislators, including MLSC President & CEO Susan Windham-Bannister, Ph.D., MassBio Director of Economic Development & Global Affairs Peter Abair, Massachusetts State Representative Jay Kaufman and Lexington Town Manager Carl Valente.

“Thanks to our growth strategy of investing in education, innovation and infrastructure, Massachusetts continues to lead the world in life sciences,” said Governor Patrick. “We welcome Xenetic to Massachusetts and look forward to their contributions to our thriving life sciences community.”

MLSC President & CEO Susan Windham-Bannister, Ph.D. said, “On behalf of the Center, I would like to welcome Xenetic to the Massachusetts life sciences community. Xenetic is focused on developing a pipeline of therapeutics for the treatment of rare diseases and Massachusetts is the perfect home for the Company’s innovative technology. We’ve worked closely with Xenetic on the company’s location decision since our first interaction with the management team during
the Governor’s UK trade mission in 2011. I’m confident that they will find the partners and talent they need to thrive right here in Massachusetts. It’s a great outcome of the Governor’s visit to the UK!”

Robert Coughlin, President & CEO of MassBio said, “We are very excited by Xenetic’s decision to relocate to Massachusetts. We look forward to working with Xenetic in the years ahead as the Company continues its growth as a U.S.-listed company.”

“I’m thrilled that Xenetic has chosen Lexington to base their US operations. Lexington continues to grow a strong bio-tech & bio-pharmaceutical cluster, thanks in large part to the aggressive efforts of the Patrick administration. I wish them all the success and look forward to working with them in the future,” stated Representative Jay Kaufman, (D-Lexington).

The company’s new corporate headquarters is located at 99 Hayden Avenue, Suite 230, Lexington, MA 02421.

About the Massachusetts Life Sciences Center

The Massachusetts Life Sciences Center (MLSC) is an investment agency that supports life sciences innovation, research, development and commercialization. The MLSC is charged with implementing a 10-year, $1-billion, state-funded investment initiative. These investments create jobs and support advances that improve health and well-being. The MLSC offers the nation’s most comprehensive set of incentives and collaborative programs targeted to the life sciences ecosystem. These programs propel the growth that has made Massachusetts the global leader in life sciences. The MLSC creates new models for collaboration and partners with organizations, both public and private, around the world to promote innovation in the life sciences. For more information, visit www.masslifesciences.com.

About Xenetic Biosciences

Xenetic Biosciences is a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics. Xenetic’s proprietary drug technology platforms include PolyXen® for creating next generation biologic drugs by extending the efficacy, safety and half-life of biologic drugs and OncoHist® for the development of novel oncology drugs focused on orphan indications. Xenetic's lead product candidates include ErepoXen®, an improved, polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease and OncoHist®, a recombinant human histone H1.3 molecule which Xenetic is developing for the treatment of refractory Acute Myeloid Leukemia (AML). Xenetic is developing a novel series of polysialylated blood coagulation factors through its license agreement with Baxter International Inc. Xenetic is also developing a broad pipeline of clinical candidates for next generation biologics and novel oncology therapeutics in a number of orphan disease indications. For more information, please visit the Company's website at www.xeneticbio.com.

###

BioFlash

Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.